La chaîne d'options affiche les données clés des options sur actions de bioAffinity Technologies à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour bioAffinity Technologies..

bioAffinity Technologies (NASDAQ:BIAF) Stock, Chaîne d'Options

bioAffinity Technologies

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies Inc

Press Releases

bioAffinity Technologies Announces Closing of $4.8 Million Public Offering

Offerings

WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m

bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025

bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025

BIAF

BIAFW

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Evogene

Galecto

Genprex

Imunon

IN8bio

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Mustang Bio

Marker Therapeutics

Neuphoria Therapeutics Inc. - Common Stock

Neuphoria Therapeutics

OSR Holdings

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sunshine Biopharma

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Soligenix

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

Comments

bioAffinity Technologies

bioAffinity Technologies (BIAF) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL